GlassScriptPhysician profile
Natalie Mercado
NPI 1669779278
$5,916.53
in general payments reported to CMS, 2019-2025
28 companies · $1,877 in 2025
The $1,877 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,607 · 2024: $2,433 · 2025: $1,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,837 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,836.54 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $913.01 | 2023-2025 | Zoryve |
| Kerecis Limited | $908.93 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Abbvie INC. | $600.90 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $595.82 | 2023-2025 | |
| Genzyme Corporation | $332.57 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $320.48 | 2023-2025 | Dupixent, Libtayo |
| Amgen INC. | $310.44 | 2023-2025 | Otezla, Otezla |
| Lilly USA, LLC | $267.19 | 2023-2024 | Olumiant, Taltz |
| Galderma Laboratories, L.P. | $237.14 | 2024-2025 | Nemluvio |
| Dermavant Sciences, INC. | $202.30 | 2023-2024 | Vtama |
| Smith+Nephew, INC. | $154.22 | 2023-2025 | Collagenase Santyl |
| E.R. Squibb & Sons, L.L.C. | $147.69 | 2023 | Sotyktu |
| Convatec INC. | $141.33 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $134.03 | 2023-2025 | |
| Ucb, INC. | $121.13 | 2024 | Bimzelx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.09 | 2025 | Spevigo |
| Boston Scientific Corporation | $85.70 | 2024 | Watchman Flx |
| Leo Pharma INC. | $77.32 | 2024-2025 | Adbry, Anzupgo |
| Organogenesis INC. | $49.10 | 2024 | |
| Kyowa Kirin, INC. | $45.88 | 2023-2025 | Poteligeo |
| Hill Dermaceuticals, INC. | $25.31 | 2023 | Tolak |
| Lnhc, INC | $23.37 | 2025 | Zelsuvmi |
| Botanix Sb INC | $19.88 | 2025 | Sofdra |
| Journey Medical Corporation | $19.47 | 2025 | |
| Paratek Pharmaceuticals, INC. | $16.86 | 2024 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.95 | 2025 | Siliq |
| Janssen Biotech, INC. | $15.81 | 2025 | Tremfya |
| Krystal Biotech INC | $14.61 | 2024 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Mercado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.